Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.

This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

"We must not be left behind with new prostate cancer treatments." PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials. Information	Understanding the possible benefits for patients when participating in a clinical trial. Clinical trials offer important and unique benefits to patients. Information
Dr. J. Carter Presents Clinical Trials 101 Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials. Information	What Are Clinical Trials? Information that all patients need to know when considering enrolling into a clinical trial. Information
CheckMate 9KD This is a clinical research study for men with metastatic prostate cancer (cancer that has spread) that no longer responds to androgen deprivation therapy treatments that lower testosterone. Information	ARASENS Clinical Trials Summary For men who have metastatic cancer and who have never been treated with chemotherapy or immunotherapy. Information
IPATential150 Clinical Trial This trial is for patients with metastatic castration-resistant Prostate Cancer who are eligible for, but have not yet begun, abiraterone (Zytiga) treatment. Information	Triton 2 Clinical Trial For patients with metastatic castration resistant prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy Information
Triton 3 Clinical Trial For patients where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of BRCA1, BRCA2, or ATM genetic mutations or alterations Information	EMBARK Clinical Trial Summary For patients with a rising PSA after being treated with surgery, radiation or both. Information
ENACT Clinical Trial Summary For patients considering active surveillance or currently undergoing active surveillance. Information	The TRUMPET Registry For men whose prostate cancer has grown or spread despite use of hormonal treatments to lower their PSA; Known as castration-resistant prostate cancer. Information
Actively Recruiting Trials by Class of Drug A description of the classes of drugs being studied for prostate cancer treatment with a selective listing of actively recruiting trials by class. Information	A listing of all the prostate cancer clinical trials listed on clinicaltrials.gov that are currently recruiting patients. Information
Prostate Cancer Clinical Trial Opportunities & Possible Benefits J. J. Carter, MD, MPH, Assistant Professor, Harvard Medical School, PHEN Medical Advisor video presentations about Prostate Cancer Clinical Trial Opportunities & Possible Benefits Information	Strategies For Increasing African American Participation in Clinical Trials at Duke Dr. Steven Patierno, Deputy Director, Duke Cancer Institute at Duke Medical Center presents at PHEN's 2016 Summit. Information
Overcoming Barriers to Clinical Trials Participation Dr. Edith Mitchell, Director, Center to Eliminate Cancer Disparities, Sidney Kimmel Cancer Center at Thomas Jefferson University presents at PHEN's 2016 Summit. Information	PHEN's Clinical Trials Rally Progress and Strategies Dr. Gary L. Taylor, PHEN Medical Director of the Clinical Trials Rally presents at PHEN's 2017 Summit. Information
Making Progress In African American Clinical Trial Enrollment Dr. Gwendolyn Shang, Director of Medical Affairs at Pfizer, outlines progress being made in partnership with PHEN at 2017 Summit. Information	Role of The Industry Advocacy Director in Clinical Trials Ms. Gissoo Decotis, Deputy Director, Oncology Advocacy Relations at Bayer Healthcare, outlines the important role of internal industry advocacy at PHEN's 2017 Summit. Information